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of Acute Achilles Tendon Ruptures
A Pilot Economic Decision Analysis
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Rick W. Wright,* MD, and Robert H. Brophy,*‡ MD
Investigation performed at the Department of Orthopaedic Surgery,
Washington University in St Louis, St Louis, Missouri, USA
Background: The operative treatment of Achilles tendon ruptures has been associated with lower rerupture rates and better
function but also a risk of surgery-related complications compared with nonoperative treatment, which may provide improved
outcomes with accelerated rehabilitation protocols. However, economic decision analyses integrating the updated costs of both
treatment options are limited in the literature.
Purpose: To compare the cost-effectiveness of operative and nonoperative treatment of acute Achilles tendon tears.
Study Design: Economic and decision analysis; Level of evidence, 2.
Methods: An economic decision model was built to assess the cost-utility ratio (CUR) of open primary repair versus nonoperative
treatment for acute Achilles tendon ruptures, based on direct costs from the practices of sports medicine and foot and ankle
surgeons at a single tertiary academic center, with published outcome probabilities and patient utility data. Multiway sensitivity
analyses were performed to reflect the range of data.
Results: Nonoperative treatment was more cost-effective in the average scenario (nonoperative CUR, US$520; operative CUR,
US$1995), but crossover occurred during the sensitivity analysis (nonoperative CUR range, US$224-US$2079; operative CUR
range, US$789-US$8380). Operative treatment cost an extra average marginal CUR of US$1475 compared with nonoperative
treatment, assuming uneventful healing in both treatment arms. The sensitivity analysis demonstrated a decreased marginal CUR
of operative treatment when the outcome utility was maximized, and rerupture rates were minimized compared with nonoperative
treatment.
Conclusion: Nonoperative treatment was more cost-effective in average scenarios. Crossover indicated that open primary repair
would be favorable for maximized outcome utility, such as that for young athletes or heavy laborers. The treatment decision for
acute Achilles tendon ruptures should be individualized. These pilot results provide inferences for further longitudinal analyses
incorporating future clinical evidence.
Keywords: Achilles tendon; decision analysis; cost-effectiveness
The optimal treatment approach for acute Achilles tendon
ruptures is evolving and controversial.9,22 Common mea-
sures to assess the effectiveness of treatment include rerup-
ture rate, posttreatment complications, subjective and
objective outcome measurements, and time to return to
play or work.7,9,19,21,29 Open surgical repair has tradition-
ally been considered the gold standard for active patients.6
Nonoperative treatment has demonstrated comparable
rerupture rates and similar functional recovery when
incorporating accelerated functional rehabilitation proto-
cols that allow earlier weightbearing and more aggressive
progression in ankle range of motion.1,2,19,23,29,30
Quantitative decision analyses can be used to assess
medical decision making through a decision tree that inte-
grates variables such as the outcome utility, costs, and
probabilities of events for each treatment arm. Expected
utility value analyses can predict the utility values for each
arm as the proxy for its effectiveness, which can serve as
the basis for cost-effectiveness analyses to assess the eco-
nomic impact of treatment. There are limited decision anal-
ysis reports in the current literature for the management of
acute Achilles tendon ruptures. A recent study slightly
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supported the cost-effectiveness of surgical treatment
according to data prospectively collected at a single institu-
tion in Sweden,27 while another study based on a claims
database in the United States (US) showed a lower cost of
nonoperative treatment from the payer’s perspective.20 The
most recent expected value decision analysis based on data
in the US, published in 2002, concluded that open surgical
repair may be the preferred treatment option because of its
superior patient outcome utility value.11
In light of new evidence comparing operative and nonop-
erative treatment and the relative paucity of studies on the
cost-effectiveness of treating Achilles tendon ruptures, the
purpose of the present study was to compare the cost-
effectiveness of open surgical repair and nonoperative
treatment of acute Achilles tendon ruptures.
METHODS
Study Design
This study was an economic decision analysis with multi-
way sensitivity analyses based on actual direct cost data,
expected utility values from a previously published decision
analysis,11 and outcome probabilities from a recent level 1
systematic review.28 In short, utility values serve as a sur-
rogate for patient-reported satisfaction with the treatment
results. Probabilities reflect how likely each treatment
result will ensue.
The analytical model was built on a decision tree. The
initial binary decision node led to 2 arms of treatment,
represented by 2 chance nodes: (1) operative (OP; open sur-
gical repair) and (2) nonoperative (NOP). Subsequent ter-
minal events in each treatment arm were represented by 5
terminal nodes—(1) well-being, (2) rerupture of the Achil-
les tendon, (3) major complication, (4) moderate complica-
tion, and (5) minor complication—similar to the algorithm
as previously described11 (Figure 1A).
Definition of Events and Variables
The 5 terminal events were defined as previously described
in a high-quality systematic review28 and a decision
analysis.11 Major complications were defined as one of the
following: deep vein thrombosis or pulmonary embolism
either after OP or NOP treatment or a deep infection that
required a surgical intervention. Moderate complications
were defined as one of the following: a superficial infection
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Figure 1. The (A) decision tree and (B) foldback analysis for the clinical decision scenario of an acute Achilles tendon rupture.
c: decision node;: chance node; D : terminal node. The probability and utility values shown at the terminal nodes were average
values, with the ultimate utility values from the foldback analysis shown at the chance nodes, together with the average and range
of direct costs.
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or wound dehiscence that did not require a surgical inter-
vention or sural nerve disturbance (after either OP or NOP
treatment).Minor complicationswere defined as skin adhe-
sion at the rupture site (after either OP or NOP treatment)
and noncosmetic scarring. Each of these 3 terminal events
as well as the other 2 events (well-being and reruptures)
was associated with 3 key variables in the analytical model:
 Probability (P; unitless): the probability of the occur-
rence of each of the terminal events after either OP or
NOP treatment
 Utility (U; unitless; range, 0-10): subjective outcome
measurement from the patients’ perspective
 Direct cost (C; US$): cost of each treatment arm from the
payers’ perspective
The detailed methods can be found in the Appendix.
Probability Data Acquisition
Probabilities (P) were populated from a level 1 systematic
review comparing primary open repair versus nonoperative
treatment for acute Achilles tendon ruptures.28
The reported pooled rate of reruptures was assigned as
POP-rerupavg and P
NOP-rerup
avg to represent the average prob-
ability for the terminal node of reruptures in the OP and
NOP arms, respectively. The range of rerupture probabili-
ties for each arm was represented by POP-rerupmin and





minimal and maximal probabilities for the OP and NOP
arms, respectively. These were determined by the minimal
and maximal rates among the 7 individual publica-
tions4,13,14,16,17,21,29 assessed in the systematic review.
The pooled rates as well as the minimal and maximal
rates of all the complications reported in the systematic
review28 were categorized under the 3 terminal nodes of
major complications, moderate complications, and minor
complications and were then summed to represent the
average and range of probabilities for each arm. The
remaining probability values outside of the rerupture and
complication rates were then assigned to the terminal node
of well-being of each treatment arm.
Outcome Utility Data Acquisition
The outcome utility (U) was represented as a unitless, con-
tinuous visual analog scale score from 0 to 10, with 0 being
the worst and 10 being the best possible subjective outcome.
The utility value for each of the 5 terminal events was
assigned as previously described in a study assessing
expected values for primary open repair versus nonopera-
tive treatment.11 In short, a group of patients were asked to
complete a questionnaire that simulates the life scenarios
of the 5 terminal events for the OP and NOP treatment
arms. The average and range of utility values were then
determined by the mean value (and the span of 1 standard
deviation above and below such a value) reported in the
study.
Cost Data Acquisition
Cost data (C) were obtained from the billing department of
a major tertiary care university medical center. The data
were pooled from the practices of 8 fellowship-trained
sports medicine and foot and ankle orthopaedic surgeons
over 2 years. The present study utilized the direct costs
from the payers’ perspective.
The cost of the OP treatment arm was the sum of pay-
ments for surgeon’s fees, hospital fees, anesthesiologist’s
fees, physical therapy, and outpatient clinic visits outside
of the 90-day global period as well as associated medical
devices. The cost of the NOP treatment arm was the sum of
payments for physical therapy and outpatient clinic visits as
well as associated medical devices. The cost for 1 outpatient
clinic visit was on par with that for 1 outpatient physical
therapy visit. The average costs for OP and NOP treatment
were represented by COPavg and C
NOP
avg, respectively.
Both the OP and NOP arms were assumed to undergo
accelerated rehabilitation protocols, as previously
described.29 The total numbers of outpatient physical
therapy and clinic visits were similar between the
2 arms.
Foldback Analysis for Expected Utility Values
A foldback analysis was performed to determine the ultimate
utility values for theOPandNOP treatment arms. For either
treatment arm, the contribution of each of the 5 terminal
events to the utility values was determined by the product
of U and P and was subsequently summed to reach the ulti-












The average cost-utility ratio (CUR) was determined by nor-
malizing the ultimate cost to the ultimate utility value, des-
ignated as CUROPavg and CUR
NOP
avg, respectively, for the









The possible range of utility values, probabilities of events,
and direct costs was included in the analytical model to
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account for the variability of such data. The highest possi-
ble CUR was determined by implementing the highest pos-
sible ultimate utility value and lowest possible cost, and
vice versa. The highest possible ultimate utility value was
computed by maximizing the probability ofwell-being, min-
imizing the probabilities of the other 4 events, and imple-
menting the maximal utility value for each event. The
range of CURs for the OP and NOP arms was determined
accordingly.
Multiway Sensitivity Analyses
for Marginal Cost per Utility
The marginal cost per utility indicated the extra cost
that the payers needed to pay for OP treatment as
opposed to NOP treatment for 1 unit of utility, defined
as “marginal CUR”: DCUR ¼ CUROP  CURNOP. The
sensitivity analyses assessed the effect of the (1) mar-
ginal utility of well-being and (2) marginal rate of rerup-
tures on DCUR.
The marginal utility was defined as the assumptive
gap of (UOP-Well  UNOP-Well) in a spectrum of 0 to 9.8,
respectively, corresponding to UOP-Wellavg, U
OP-Well
min,
and UOP-Wellmax. Such an analysis evaluated the assump-
tive scenario when OP treatment resulted in better than
average outcomes for higher demanding patients (higher
marginal utility) or else equal outcomes as compared
with NOP treatment for lower demanding patients
(marginal utility ¼ 0).
The marginal rate of reruptures was defined as the
assumptive gap of (PNOP-rerup  POP-rerup) in a spectrum of
0% to 20%, respectively, corresponding to PNOP-rerupavg,
PNOP-rerupmin, and P
NOP-rerup
max. Such an analysis evaluated
the assumptive scenario when NOP treatment resulted in
higher than average or equal rerupture rates as compared
with OP treatment (marginal rerupture rate ¼ 0).
RESULTS
Acquired Data for Probability,
Outcome Utility, and Cost
The pooled average probabilities for reruptures were
3.6% and 8.8%, respectively, for the OP and NOP treat-
ment arms. The average probabilities for the OP versus
NOP arms of major, moderate, and minor complications
were 9.4% versus 10.2%, 8.8% versus 0.8%, and 13.1%
versus 0.6%, respectively, resulting in average well-
being probabilities of 65.1% versus 79.6%, respectively
(Table 1).
The average outcome utility of well-being for the OP
arm was 7.9, compared with 7.0 for the NOP arm. The
average and range of utilities for reruptures as well as
major, moderate, and minor complications were identical
for both treatment arms (Table 1). The average cost for OP
treatment (in US$) was $12,477 (range, $7594-$17,323)
versus $3100 (range, $1975-$4600) for NOP treatment
(Table 2).
Foldback and Cost-Utility Analyses
for Boundary Conditions
The foldback analysis revealed that the average ultimate
utility value for OP treatment was 6.3 versus 6.0 for NOP
treatment (Figure 1B). The average cost to gain 1 unit of
utility for the OP armwas approximately 3 timesmore than
that for the NOP arm (CUROPavg: $1995;CUR
NOP
avg: $520).
Multiway sensitivity analyses for boundary conditions
showed crossover of the 2 treatment arms in which the
CUROPmin could be as low as $789 and the CUR
NOP
max
could be as high as $2079 (Figure 2). This indicated that
in certain scenarios, OP treatment can be more cost-
effective than NOP treatment.
TABLE 1
Probability and Outcome Utility Data for the 5 Major Eventsa
Probability, % Outcome Utility
Average Minimum Maximum Average Minimum Maximum
Well-being (Maximum) (Minimum)
OP 65.10 95.10 14.66 7.9 6.0 9.8
NOP 79.56 95.50 31.22 7.0 5.0 9.0
Reruptures
OP 3.60 1.70 10.00 2.6 0.4 4.8
NOP 8.80 4.50 20.80 2.6 0.4 4.8
Major complications
OP 9.44 0.00 9.44 1.0 0.0 2.6
NOP 10.24 0.00 10.24 1.0 0.0 2.6
Moderate complications
OP 8.76 0.00 45.45 3.5 1.4 5.6
NOP 0.78 0.00 34.14 3.5 1.4 5.6
Minor complications
OP 13.10 3.20 20.45 4.7 2.5 6.9
NOP 0.62 0.00 3.60 4.7 2.5 6.9
aNOP, nonoperative; OP, operative.
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Multiway Sensitivity Analyses
for Marginal Cost per Utility
OP treatment cost an extra marginal CUR of $1475,
assuming the utility of well-being at the average values
of 7.9 and 7.0, respectively, for OP and NOP treatment.
The marginal CUR decreased as the marginal utility of
well-being increased. If such a utility value for OP treat-
ment reached its maximum of 9.8 and that for NOP
treatment was 7.8 (marginal utility of well-being of
2.0), OP treatment cost an extra marginal CUR of
$1196 (Figure 3A).
OP treatment cost an extra marginal CUR of $1475,
assuming the probability of reruptures at the average
values of 3.6% and 8.8%, respectively, for OP and NOP
treatment. Sensitivity analyses, allowing for a greater
advantage to OP treatment with regard to rerupture rates,
decreased the marginal CUR. Even in the most favorable
case, assuming a rerupture rate of 1.7% for OP treatment
and 21.7% for NOP treatment, however, the marginal CUR
was still $1388 (Figure 3B).
DISCUSSION
This pilot analysis revealed that operative treatment of
acute Achilles tendon ruptures had a higher incremental
cost per utility gained but also higher expected utility value
upon uneventful healing compared with nonoperative
treatment. On average, nonoperative treatment was more
cost-effective. Operative treatment became increasingly
cost-effective as the utility of well-being increased: for
example, with high-demand patients, such as athletes, or
those in physically demanding occupations who prefer the
highest possible functional outcome as early as possible.
Our study sought to provide novel information by incor-
porating actual cost data and updated outcome data into
the decision analysis model. While the basic structure of
the decision tree is similar to previous analyses,11 the prob-
abilities of each outcome are expected to change over time
because of advancement in either treatment option. In
addition to the expected utility value alone, we integrated
direct cost data with sensitivity analyses, accounting for
potential heterogeneity among various patient populations
and the associated variables.
Primary open repair for acute Achilles tendon ruptures
may lead to favorable muscle strength in the first year after
surgery16 and fewer days to return to sports4 or work.19
These benefits may not be supported by other reports, as
some factors were measured differently in various sources
in the literature and are thus difficult to compare. Primary
open repair results in lower rates of reruptures, as reflected
by the pooled rerupture rate in the most recent Cochrane
review10 and by a level 1 systematic review.28 This may be
of critical concern for active patients who need high athletic
performance or a return to physically demanding occupa-
tions. Accordingly, operative treatment may reduce the
societal costs resulting from underperformance or loss of
work days.7
Nonoperative treatment is a cost-effective option and
could be especially suitable for the general population that
is not that active. Accelerated rehabilitation protocols
with early weightbearing and range of motion progression
can lead to decreased rerupture rates and similar objective
outcomes as operative treatment.16,21,29 The complications
associated with surgery becomemuch less likely, as shown
in the pooled probabilities of moderate and minor compli-
cations in the present study. The probability of certain
major complications such as deep vein thrombosis remains
similar. The advantage of avoiding wound complications
may be offset in the near future by the advancement of
percutaneous repair techniques13 that are relatively novel
with emerging evidence to support promising midterm to
long-term outcomes.5,12 A recent retrospective cohort
analysis demonstrated that percutaneous repair could be
more cost-effective than open repair,3 although more high-
level analyses of its effectiveness, cost, and utility are
needed.
Figure 2. Sensitivity analyses for boundary conditions for
operative (OP) versus nonoperative treatment, showing a
crossover in the range between the lowest and highest
possible cost-utility ratios (CURs). The numbers for each bar
represent the minimum (left), average (middle), and maximum
(right) values.
TABLE 2
Direct Cost of OP Versus NOP Treatmenta
Average Minimum Maximum
OP (open repair)
Surgeon’s fee 1468 157 1783
Anesthesia fee 1200 1200 1200
Hospital fee 7209 4762 10,240
Outpatient visitb 2250 1125 3750
Associated medical devicec 350 350 350
Total 12,477 7594 17,323
NOP
Outpatient visitb 2250 1125 3750
Associated medical devicec 850 850 850
Total 3100 1975 4600
aData are reported as US dollars. NOP, nonoperative; OP, oper-
ative.
bOutpatient visits included clinic visits and physical therapy
sessions, which were estimated as an average of 22.5 visits (range,
15 to 30 visits) in total for both OP and NOP treatment, with the
average direct cost of $100 (range, $75-$125).
cOne boot and 1 set of crutches were included for both OP and
NOP treatment; an additional cost of short leg casting was applied
to NOP treatment.
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Sensitivity analyses reflecting lower rerupture rates
after primary surgical repair and higher rerupture rates
after nonoperative treatment narrowed the cost advan-
tage for nonoperative treatment, but only slightly, as
shown in Figure 3B. Even under the scenario of a 20%
higher rerupture rate after nonoperative treatment com-
pared with primary surgical repair, operative treatment
was still more expensive. However, while there is still var-
iation regarding the rerupture rates of either treatment
option in the literature, the difference in rerupture rates
may be particularly important to certain patients depend-
ing on their lifestyle and expectations. In addition, the
costs of managing reruptures after initial treatment, be
it operative or nonoperative, can affect the overall cost-
effectiveness should these costs be included in future
analyses. Therefore, one should use caution in the inter-
pretation of the results.
Surgical treatment for acute Achilles tendon ruptures
was found to be cost-effective in a prospective randomized
cohort study from Sweden.27 Using quality-adjusted life
years (QALYs) as the measure for the effectiveness of
treatment, the incremental cost-effectiveness ratio was
€45,885 per QALY, resulting in a 57% likelihood for sur-
gical treatment to be cost-effective based on the €50,000
threshold of willingness to pay for 1 QALY. The rerupture
rate was 10% and 2.3% in their cohort, as opposed to 8.8%
and 3.6% in the present study, for nonoperative and oper-
ative treatment, respectively. Further, the costs and
health care infrastructure are distinct in different coun-
tries and may thus affect the cost-effectiveness of a variety
of treatment strategies.
Nonoperative treatment may be favorable for cost mini-
mization from the payer’s perspective based on a claims
database in the US.20 The rates and associated costs of
managing complications did not significantly differ
between operative and nonoperative treatment. Based on
claims data, there appeared to be a trend toward treating
more of these Achilles tendon ruptures nonoperatively,
whereas younger patients were more likely treated with
surgery. These findings, although largely based on the
claims that the payers processed and focused on costs only,
resonated with our results, which were drawn from actual
cost data integrated with utility scores for cost-
effectiveness analyses.
Both QALY and utility values are common proxies to
quantify the effectiveness of treatment in cost-
effectiveness analyses. Because Achilles tendon ruptures
do not directly affect life expectancy, using QALY requires
the collection of subjective patient-reported outcomes,
which may be essentially on par with the acquisition of
utility values. The use of US$50,000 per QALY as the
willingness-to-pay threshold in the US can be traced back
to discussions in the 1970s on Medicare coverage for
patients with end-stage renal disease.8 Revising such a
threshold has been proposed to better reflect the current
health care system and the needs of modern society.15 Fur-
ther justification is needed for its use in orthopaedic surgi-
cal procedures, particularly when patients’ willingness to
pay may widely vary based on their expected functional
outcome, which is paramount in the practice of sports med-
icine as well as foot and ankle surgery.
The scenario of chronic Achilles tendon ruptures was not
analyzed in the present study. These patients commonly
require more complex procedures such as soft tissue flaps,
tendon transfer or augmentation, or bridging materi-
als.18,24-26 The cost of such procedures is presumably
higher, and the outcome may be suboptimal compared with
the treatment of acute ruptures. The cost-effectiveness of
various treatment options in such a scenario may be diffi-
cult to assess because of a lack of sufficient case volume and
homogeneity in the published literature.
Figure 3. Sensitivity analyses for marginal cost-utility ratio (DCUR) of operative (OP) treatment as opposed to nonoperative
(Non-OP) treatment, implicating that OP treatment becomes increasingly cost-effective as its utility of well-being further exceeds
Non-OP treatment and its rerupture rate minimizes, which could be the scenario of treating certain young, active athletes. (A) DCUR
decreases as the utility of Non-OP treatment falls further behind OP treatment. (B) Decrease of DCUR as a function of increasing
rerupture probability of Non-OP treatment compared with OP treatment. Note that in most scenarios, Non-OP treatment is still
more cost-effective than OP treatment.
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Limitations
As a pilot investigation, the present study did have several
limitations. First, the data of costs, utilities, and probabil-
ities were not acquired from exactly the same patient popu-
lation. Second, we assessed only the direct costs from the
payers’ perspective and did not consider the societal costs
attributed to loss of work days and school days alike. The
outcomeutilitywaspopulated fromsubjectivepatient reports
and did not include quantitative measurements such as
ankle push-off strength, which may affect athletic patients’
performance and thus place more emphasis on utility. Also,
the cost data were from a single academic institution.
In addition, our decision model did not account for the
full time horizon of each treatment arm, which may intro-
duce additional costs resulting from further management of
reruptures and other complications. The potential costs
associated with complication management could be sub-
stantial, depending on the type of complication, the
expected outcome, and the underlying medical condition
of each patient. To date, there is insufficient high-level
evidence to support secondary analyses assessing the
cost-effectiveness of these complications. The results could
differ if such costs were incorporated in the future.
Despite these limitations, we optimized the validity of
this pilot study by incorporating data from the best avail-
able level 1 evidence as well as by performing multiway
sensitivity analyses.
Future Directions
This analysis can serve as a foundation for future investi-
gation. The decision tree could further expand based on this
economic decision model, as more high-level evidence
becomes available regarding the cost and utility of compli-
cation management as well as percutaneous Achilles ten-
don repair procedures.
CONCLUSION
While practicing cost-effective medicine, optimizing out-
comes as they relate to patients’ expectations for their work
and life should remain the surgeon’s top priority. In the
current study, nonoperative treatment was cost-effective
for the average patient population. This remained true
when the expected utility value decreased, as in patients
with lower physical demands, as well as when the surgical
complication rates increased, as in patients with medical
comorbidities. Primary open repair was less cost-effective
in the average scenario. However, its cost-effectiveness
increased when a higher utility value was expected, as in
young athletes or patients with higher physical demands.
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avg, which represented the average probabilities of the well-being terminal node for the OP and NOP
arms, respectively, were determined by the following:
POP-wellavg¼ 100%  POP-rerupavgþ POP-majavgþ POP-modavgþ POP-mnravg
 
and
PNOP-wellavg¼ 100%  PNOP-rerupavgþ PNOP-majavgþ PNOP-modavgþ PNOP-mnravg
 
:
The minimal probabilities of well-being, POP-wellmin and P
NOP-well
min, were determined by the “maximal” probabilities of the
other 4 terminal nodes and vice versa:
POP-wellmin¼ 100%  POP-rerupmaxþ POP-majmaxþ POP-modmaxþ POP-mnrmax
 
and




















avg, respectively. The range of




































max, respectively, for the OP and NOP arms.
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Multiway Sensitivity Analyses for Boundary Conditions







UOPSUM; max ¼ UOP-wellmax  POP-wellmax þUOP-rerupmax  POP-rerupmin þUOP-majmax  POP-majmin þUOP-modmax  POP-modmin þUOP-mnrmax  POP-mnrmin
The range of CURs for the OP and NOP arms was then determined accordingly.
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